Melbourne, April 26, 2026, 23:01 (AEST)
- CSL repurchased 101,810 shares on April 23, according to its latest ASX filing.
- CSL’s buyback followed a Reuters report showing the stock had sunk to lows not seen since 2017.
- Weaker U.S. flu-shot demand and an ongoing earnings reset are front of mind for investors, even as they consider the buyback.
CSL Limited snapped up 101,810 shares for A$13.1 million on April 23 as part of its ongoing on-market buyback, according to a filing dated April 24. The Australian biotech pushed forward with the purchases—even with its shares coming under renewed pressure after a U.S. military policy shift that could weigh on flu vaccine sales. The buyback prices ranged from A$127.98 to A$129.98. CSL Limited
Timing is crucial here. CSL’s working to prove balance-sheet restraint after investor confidence took a big hit, just as the market is rethinking its view of the company’s vaccine arm following the Pentagon’s move to drop mandatory flu shots for U.S. troops. According to Reuters, CSL shares slid to lows not seen since late August 2017, down over 25% so far this year. Reuters
CSL’s latest update puts total shares repurchased so far at just shy of 6 million, with cumulative spend reaching about A$1.01 billion on an Australian-dollar basis. The company still plans to buy back as much as US$750 million worth of ordinary shares through the program, which is set to conclude on June 30. CSL Limited
Sentiment around CSL Seqirus, the vaccine arm, took a hit after the Pentagon’s move. Defense Secretary Pete Hegseth said U.S. troops are no longer required to get flu shots, dealing a blow to the business. Sanofi, CSL Seqirus, GSK, and AstraZeneca didn’t immediately respond to requests for comment, according to Reuters. Reuters
Marc Jocum, senior product and investment strategist at Global X ETFs, called “the Pentagon’s move” a “meaningful catalyst for the sell-off” in remarks to Reuters. For CSL, the timing couldn’t have been worse, he said, with the company already under strain from tepid U.S. flu vaccine uptake and weaker Seqirus results. Reuters
Vantage Markets analyst Hebe Chen told Reuters the problem runs deeper than a single policy adjustment, highlighting “slowing earnings momentum, a more volatile vaccine segment” and uncertainty around CSL’s future direction. That’s what has shareholders on edge. The buyback helps EPS, but doesn’t address demand head-on. Reuters
CSL’s first-half numbers set a clear tone. The company posted underlying NPATA of US$1.9 billion in February, marking a 7% decline; NPATA, for context, excludes amortisation on acquired intellectual property and significant one-offs. Net profit after tax, as reported, plunged 81% to US$401 million, reflecting restructuring charges and impairments. CSL also lifted its buyback, bumping it up from US$500 million to US$750 million.
Back then, CSL chief financial officer Ken Lim called out the company’s performance—“clearly not satisfied”—while pointing to an “ambitious growth plan” for the second half. That plan hinges on immunoglobulin, albumin, and a slate of newer products. Immunoglobulin, for context, are antibody-based plasma therapies for immune and other tough disorders.
CSL Behring still anchors the company, producing plasma-based therapies, gene treatments, and similar drugs. CSL Seqirus is another key unit, specializing in flu vaccines and pandemic-related offerings. Then there’s CSL Vifor, supplying medicines for iron deficiency and kidney conditions. Reuters
CSL told investors it doesn’t anticipate significant impact from proposed U.S. tariffs on imported pharmaceuticals across most of its U.S. product sales, though it’s still ironing out some specifics. The company emphasized that its plasma therapies for the U.S. are made with plasma collected solely within the country. As for Fluad—the top CSL Seqirus product in the U.S.—production happens in the UK, where CSL expects the tariff to drop to zero.
Multiple headwinds could hit simultaneously. If the U.S. flu season disappoints, plasma collections crawl back more slowly, generic iron drugs gain ground, or tariffs break against CSL, the company may need to ramp up cost reductions and accelerate buybacks as shareholders look for concrete signs of earnings growth.
The picture is muddled for now. CSL is snapping up shares at levels not seen in years, yet this latest buyback comes as the market remains unsure if the former Australian growth favorite can regain speed quickly enough.
